PFI Q2 financials
This article was originally published in The Tan Sheet
Executive Summary
Two long-term supply agreements with drug companies, in addition to spring launch of generic ibuprofen-pseudoephedrine (Whitehall's Advil Cold & Sinus), should "significantly enhance sales and earnings over the next two to three years," private labeler says Feb. 13. Sales for fiscal second quarter ended Dec. 29 rose 8.4% to $12.9 mil., with quarterly loss of $2.9 mil. For the six months, sales edged up 4% to $26.1 mil., with net loss of $4.9 mil...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.